Cargando…
EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition
Expression of EGFRvIII is frequently observed in glioblastoma and is associated with increased cellular proliferation, enhanced tolerance to metabolic stresses, accelerated tumor growth, therapy resistance and poor prognosis. We observed that expression of EGFRvIII elevates the activation of macroau...
Autores principales: | Jutten, Barry, Keulers, Tom G., Peeters, Hanneke J. M., Schaaf, Marco B. E., Savelkouls, Kim G. M., Compter, Inge, Clarijs, Ruud, Schijns, Olaf E. M. G., Ackermans, Linda, Teernstra, Onno P. M., Zonneveld, Marijke I., Colaris, Resi M. E., Dubois, Ludwig, Vooijs, Marc A., Bussink, Johan, Sotelo, Julio, Theys, Jan, Lammering, Guido, Rouschop, Kasper M. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902239/ https://www.ncbi.nlm.nih.gov/pubmed/29377763 http://dx.doi.org/10.1080/15548627.2017.1409926 |
Ejemplares similares
-
EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016) -
Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020) -
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
por: Hoogstrate, Youri, et al.
Publicado: (2021) -
Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010) -
Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)